OBJECTIVE -To determine the efficacy of rosiglitazone compared with placebo in reducing hyperglycemia.
T ype 2 diabetes is often characterized by hyperglycemia as a result of increased insulin resistance in hepatic/ peripheral tissues and pancreatic ␤-cell dysfunction (1-3). Improved glycemic control is associated with reductions in long-term microvascular complications (4) and improved survival rates (5) . However, monotherapy with sulfonylureas or metformin is often insufficient to sustain glycemic control, indicating a need for additional therapeutic agents (6) .
Thiazolidinediones, a new class of oral antidiabetic agents, reduce hyperglycemia by decreasing insulin resistance in peripheral tissues (3, 7) . They act by binding to the peroxisome proliferator-activated receptor-␥ (PPAR-␥) (8) and altering expression of components that influence insulin signaling and glucose transport systems (3) . Rosiglitazone is a potent member of the thiazolidinedione class, with a binding affinity for PPAR-␥ that is ϳ100-fold greater than that of pioglitazone and 190-fold greater than that of troglitazone (9) .
The primary objectives of this study were to examine the efficacy of rosiglitazone in reducing HbA 1c and to evaluate the therapeutic equivalence of once-daily and twice-daily dosing regimens.
RESEARCH DESIGN AND METHODS

Study design
The efficacy of rosiglitazone was assessed in a multicenter double-blind randomized placebo-controlled trial in 65 centers in the U.S. Oral antihyperglycemic agents were discontinued at least 14 days before a 4-week placebo run-in period. Patients were then randomly assigned to receive placebo or rosiglitazone 4 
Patients
Eligibility requirements included the following: age 40-80 years, BMI 22-38 kg/m 2 , type 2 diabetes as defined by the National Diabetes Data Group (10), fasting plasma glucose 7.8-16.7 mmol/l (140-300 mg/dl), and fasting C-peptide Ն0.27 nmol/l (Ն0.8 ng/ml) at the time of screening. Patients with clinically significant renal disease, New York Heart Association (NYHA) class III/IV coronary insufficiency or congestive heart failure, symptomatic diabetic neuropathy, or elevations in total bilirubin, alkaline phosphatase, alanine aminotransferase (ALT), or aspartate aminotransferase Ͼ2.5 times the upper limit of the reference range were excluded.
Efficacy and safety measurements
The change from baseline (end of the 4-week placebo run-in period) after 26 weeks of treatment was assessed for the primary efficacy parameter of HbA 1c and the secondary efficacy parameters of fasting plasma glucose, immunoreactive insulin, C-peptide, and lipid levels.
Clinical chemistry, hematology, liver enzymes, and urinalysis were performed at SmithKline Beecham Clinical Laboratories (Van Nuys, CA) on fasting samples obtained at weeks Ϫ4, Ϫ2, 0 (baseline), 4, 8, 12, 18 , and 26. Plasma glucose, total cholesterol, HDL cholesterol, and triglycerides were measured by an Olympus analyzer (Olympus Clinical Instruments Division, Lake Success, NY), HbA 1c by Variant high-performance liquid chromatography (Bio-Rad, Hercules, CA), C-peptide by radioimmunoassay (Diagnostic Products, Los Angeles, CA), insulin by radioimmunoassay (Pharmacia, Uppsala, Sweden), and free fatty acids by enzymatic/colorimetric analysis (Wako Diagnostic, Richmond, VA) using a COBAS analyzer (Roche Diagnostic Systems, Indianapolis, IN). LDL cholesterol concentrations were estimated using the Friedewald equation (11) when triglycerides were Ͼ400 mg/dl. Overall, 14% of patients were excluded from the LDL calculation: 1.0% due to baseline triglyceride levels Ͼ400 mg/dl; 9.0% due to week 26 triglyceride levels Ͼ400 mg/dl; 0.8% due to week 26 HDL values missing; 3.0% due to baseline and week 26 triglyceride levels Ͼ400 mg/dl; and 0.3% due to week 26 triglyceride levels Ͼ400 mg/dl. (12) . HOMA has been validated by comparison with glucose clamps (13,14) and intravenous glucose tolerance tests with minimal model analysis (12, 14, 15) and has been used to assess both insulin resistance and ␤-cell function in epidemiological studies (16, 17) .
Data analysis
So that changes in glycemic control could be assessed, the primary efficacy population consisted of all patients who had at least one postbaseline data point for any efficacy parameter, carrying forward the last observation in the case of missing data or early withdrawals. The lipid and safety assessments were based on observed data for all randomized patients.
Treatment groups were compared using analysis of covariance with terms for baseline, treatment, and geographic region. Since the lipid data did not meet normality and homogeneity of variance assumptions required for parametric analysis, a nonparametric assessment was based on the distribution of the percentage change in lipid values; medians and 95% CIs were estimated, and pairwise comparisons to placebo were conducted using Dunnett' s multiple comparison procedure to maintain a two-sided 0.05 significance level. Lipid subset analyses used the same nonparametric methods.
Equivalence Safety parameters, including clinical laboratory tests, vital signs, and body weight, were examined using one-way analysis of variance.
HOMA estimates were expressed relative to values in a lean nondiabetic reference population that was 18-25 years of age (13, 14) .
RESULTS
Baseline characteristics
Of the 1,503 patients screened, 959 were randomized to treatment. Among those patients excluded, 77% failed to meet the inclusion criteria; the remainder experienced adverse events before randomization (7.5%), withdrew consent (10%), deviated from the protocol (2.2%), or were lost to follow-up (5%). Baseline characteristics were similar in all treatment groups (Table 1 ). In addition, the baseline characteristics of patients who achieved an HbA 1c concentration Յ7% were similar to those patients who did not. Before the study, ϳ25% of patients were treated with diet alone, 60% with a single antihyperglycemic agent, and 15% with multiple agents.
Glycemic control
All rosiglitazone-treated groups had significant decreases in HbA 1c compared with 8.9 ± 1.5 8.9 ± 1.6 8.9 ± 1.5 8.9 ± 1.5 9.0 ± 1.5 Baseline fasting plasma 12.5 ± 3.2 12.7 ± 3.4 12.5 ± 3.1 12.7 ± 3.2 12.7 ± 3.2 glucose (mmol/l) Duration of diabetes (years)
6.6 ± 6.9 5.4 ± 6.1 5.5 ± 4.9 6.1 ± 6.7 5.9 ± 6.1
Data are means ± SD, or n (%). RSG, rosiglitazone. At baseline, the patients who were withdrawn from prior antihyperglycemic therapy had been off medication for 6 weeks.
Rosiglitazone reduces blood glucose the placebo group (P Ͻ 0.0001). Mean treatment effects were Ϫ0. (Fig. 1B) ; at study end, HbA 1c concentration Յ7.0% was achieved by 38, 25, 31, and 40% of patients in each group, respectively, compared with 17% using placebo.
In patients who had received prior oral monotherapy, rosiglitazone 4 mg o.d., rosiglitazone 2 mg b.i.d., rosiglitazone 8 mg o.d., and rosiglitazone 4 mg b.i.d. altered HbA 1c concentration from baseline by ϩ0.14, ϩ0.02, Ϫ0.26, and Ϫ0.54%, respectively, compared with an increase of 0.98% with placebo (Fig.  1B) . At study end, HbA 1c concentration Յ7% was achieved by 21, 21, 13, and 25% of patients in each group, respectively, compared with 6% of patients in the placebo group.
In patients who had previously received a combination of oral antihyperglycemic agents, only rosiglitazone 4 mg b.i.d. produced a decrease from baseline in HbA 1c concentration (Ϫ0.43% , Fig. 1B) ; at study end, 33% of these patients achieved HbA 1c concentration Յ7%, compared with 0% of patients taking placebo.
Serum lipids
In general, statistically significant dosageordered decreases in free fatty acid levels were observed in all rosiglitazone treatment groups, compared with baseline and with placebo (except in the rosiglitazone 4 mg o.d. group) in patients who completed 26 weeks of treatment (Table 2) . Small but statistically significant increases in total cholesterol and LDL cholesterol were observed in all treatment groups (including placebo) as compared with baseline, as well as in rosiglitazone treatment groups compared with placebo (Table 2) . Statistically significant increases in HDL cholesterol, compared with baseline, were observed in all treatment groups ( Table 2 ). The median percentage changes from baseline for the LDL cholesterol:HDL cholesterol ratio were small and were generally not statistically significant. In comparison with placebo, there were small but statistically significant increases in the rosiglita- 
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Rosiglitazone reduces blood glucose
In patients with baseline LDL cholesterol Յ3.36 mmol/l (130 mg/dl) (the LDL cholesterol cutoff of 3.36 mmol/l for subgroup analysis was chosen based on the guidelines of the National Cholesterol Education Program), both placebo and rosiglitazone treatments resulted in statistically significant increases in LDL cholesterol compared with baseline. When compared with placebo, these changes were generally not significant. In patients with baseline levels Ͼ3.36 mmol/l, the changes in LDL cholesterol were smaller in magnitude (Table 2) .
In general, the rosiglitazone treatment groups demonstrated small but significant increases in triglyceride levels, with greater increases observed in patients with baseline levels Յ5.17 mmol/l (200 mg/dl); however, these changes were not dosage related. When compared with placebo treatment, only increases observed with rosiglitazone 4 mg o.d. were significant. In patients with baseline triglyceride levels Ͼ5.17 mmol/l, no change was significant in any treatment group (Table 2) .
Safety
Rosiglitazone was well tolerated; the percentages of patients with at least one adverse event during therapy were comparable for rosiglitazone (75%) and placebo (71%). Hyperglycemia and headache were the most commonly cited reasons for withdrawal. Withdrawals were more common among placebo (38.4%) than among rosiglitazone (20.7%) recipients, and withdrawals due to lack of efficacy were more common with placebo (16.8%) than with rosiglitazone (6.6%). The remaining withdrawals in the placeboand rosiglitazone-treated patients were due to adverse experience (10.8 and 5.6%, respectively), protocol deviation (1.1 and 1.4%, respectively), loss to follow-up (2.2 and 2.4%, respectively), and others (7.6 and 4.7%, respectively). The patients who withdrew from treatment were more poorly controlled at baseline (mean HbA 1c concentration 9.4%).
There were 46 patients who had adverse events related to edema: 3 (1.6%) in the placebo group, 10 (5.2%) in the rosiglitazone 4 mg o.d. group, 12 (6.4%) in the rosiglitazone 8 mg o.d. group, 8 (4.1%) in the rosiglitazone 2 mg b.i.d. group, and 13 (6.6%) in the rosiglitazone 4 mg b.i.d. group. One patient in the placebo group withdrew from the study because of mild edema. Body weight decreased with placebo (Ϫ0.9 kg) but increased in a dosage-dependent manner with rosiglitazone (1.2, 1.5, 2.6, and 3.3 kg with rosiglitazone 4 mg o.d., rosiglitazone 2 mg b.i.d., rosiglitazone 8 mg o.d., and rosiglitazone 4 mg b.i.d., respectively; all P Յ 0.0001 compared with both placebo and baseline). The waist-to-hip ratio did not change significantly in any group.
Two randomized patients (one treated with placebo and one with rosiglitazone 4 mg b.i.d.) had asymptomatic elevations in serum ALT that were more than three times the upper limit of the reference range. In both patients, ALT values returned to normal as treatment continued. Small but statistically significant dosage-dependent decreases in Hb (Ϫ0.5 to Ϫ0.9 g/dl) and hematocrit (Ϫ1.6 to Ϫ2.5 percentage points) occurred in all rosiglitazone groups (P Յ 0.0001 compared with placebo and baseline). (18) . However, it should be noted that although HOMA is validated as a measure of insulin sensitivity, it is less well established as a measure of ␤-cell function. A dosage-dependent reduction in free fatty acid levels was observed with all regimens of rosiglitazone. Since free fatty acids may contribute to insulin resistance and impaired insulin secretion (19) , decreases in free fatty acid levels may contribute to the observed improvements in insulin sensitivity and glycemic control. Total cholesterol, LDL cholesterol, and HDL cholesterol increased from baseline levels in all treatment groups, with the greatest increases observed in rosiglitazone-treated patients; the increases in LDL cholesterol may be partially offset by corresponding increases in HDL cholesterol. The LDL cholesterol:HDL cholesterol ratio is often considered a better predictor of cardiovascular risk than LDL cholesterol or HDL cholesterol alone (20, 21) . Changes in the LDL cholesterol:HDL cholesterol ratio with rosiglitazone treatment were small and only modestly different from placebo. Alterations in serum triglyceride levels were small and comparable among all treatment groups, including placebo, possibly dissociating these changes from a true rosiglitazone effect. More long-term experience will be needed to determine consistent effects on lipid levels and the impact of lipid changes on cardiovascular outcomes.
CONCLUSIONS -
Rosiglitazone was generally well tolerated. Statistically significant dosage-related decreases in Hb and hematocrit were observed in all rosiglitazone treatment groups; however, these changes generally occurred within the first 90 days of treatment and remained stable thereafter. This effect is consistent with plasma volume expansion leading to fluid retention and hemodilution, observed during treatment with other thiazolidinediones (22, 23) . Rosiglitazone therapy was also associated with significant increases in weight, which may be attributed to thiazolidinedioneassociated fluid retention (22) (23) (24) , adi pocyte differentiation (22, 25) , and increased appetite (26) . Since there was no increase in waist-to-hip ratio, it is possible that these weight increases primarily reflect fluid retention and/or subcutaneous fat accumulation, both of which confer less cardiovascular risk than intra-abdominal fat (27). Rosiglitazone treatment was not associated with hepatic side effects.
The decrease in HbA 1c of 1.5% with maximum rosiglitazone dosage (4 mg b.i.d.) compares well with the effects of sulfonylureas or metformin in patient groups with comparable initial HbA 1c concentrations (ϳ9%) (28-31). Thus, because rosiglitazone has efficacy comparable to that of these agents and is not associated with either hypoglycemia or gastrointestinal intolerance, the benefits of rosiglitazone in reducing glucose levels should apply to a wide spectrum of patients with type 2 diabetes.
Overall, rosiglitazone significantly improved glycemic control and was well tolerated. Because responses varied by patients' treatment history, it appears that once-daily rosiglitazone may be sufficient as first-line therapy for patients with recent diagnoses, whereas 4 mg b.i.d. may be needed for patients with more advanced diabetes. 
